The Final Rule was mooted for implementation over a staged transition period, determined by a service’s risk level, by 2028.

Zimmer Biomet has adjusted its 2025 earnings forecast to $7.90-$8.10 per share, down from previous estimates falling between ...

Firefly Neuroscience has completed the acquisition of Evoke Neuroscience, a developer of technologies aimed at assessing ...

Natera has announced findings from a study evaluating its Signatera in individuals with soft tissue and bone sarcomas.

URA has entered the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s CGM ...

InBrain Neuroelectronics has won a €4m ($4.5m) grant from the Spanish Ministry of Industry and Tourism to develop its BCI ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to GE HealthCare's Aurora nuclear medicine system and ...

Tariffs, though designed as economic tools, have ripple effects that extend deeply into the regulatory framework of the ...

Core has completed the acquisition of neurotechnology solution provider NeuroMetrix, including its Quell platform.

Inquis Medical has reported that the trial of its Aventus thrombectomy system for pulmonary embolism (PE) met its primary ...

GE HealthCare is expecting its 2025 revenues to take a hit of around $500m due to the Trump administration’s imposition of ...

Canada’s UHN and U of T researchers have created a skin-based test that identifies progressive supranuclear palsy (PSP) ...